09:55 AM EST - HLS Therapeutics Inc. : Announces its financial results for the three and 12 months ended December 31, 2025. All amounts are in thousands of United States dollars unless otherwise stated. Fiscal 2025 revenue was $55.5 million, Adjusted EBITDA was $19.6 million and cash from operations was $17.1 million, compared to $56.6 million, $16.6 million and $8 million, respectively. Q4 2025 revenue was $15.2 million, Adjusted EBITDA was $5.7 million and cash from operations was $6.5 million, compared to $15.5 million, $5.6 million and $3.2 million, respectively. HLS Therapeutics Inc.
shares T.HLS are trading unchanged at $4.27.
